ASCO: GSK Confident In DREAMM Of Returning Blenrep To Market
DREAMM-8 Trial Is Second Trial Supporting Second-Line Use
The antibody-drug conjugate, withdrawn from market for late-line use, is poised to make a return with strong results in DREAMM-7 and 8. GSK plans to refile later this year.
